Clinical Trial Update: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This Phase 2 trial is evaluating the optimal dose, adverse events, and changes in disease activity of ABBV-706 in combination with atezolizumab versus standard …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• ABBV-706
• Atezolizumab (atezolizumab)

Snippet

Sponsor: AbbVie | Conditions: Small Cell Lung Cancer | Phase 2 | Status: RECRUITING